uiux
Regular
BRAINCHIP INC. AND NANOSE MEDICAL SUCCESSFULLY DETECT COVID-19 IN EXHALED BREATH WITH FAST HIGH-ACCURACY RESULTS
BrainChip Holdings Ltd (ASX:BRN), a leading provider of ultra-low power high performance artificial intelligence technology, today announced progress in testing with the NaNose (Nano Artificial Nose) where patients’ exhaled breath samples were tested for COVID-19.
NaNose Medical technology, based on the artificial nose developed at the Technion Israel Institute of Technology, has the same sensitivity to minute quantities of Volatile Organic Compounds (VOCs) as a dog’s nose. It has been tested by the Technion since 2017 to identify diseases including Parkinson’s, cancers, kidney failure, multiple sclerosis and infectious diseases such as COVID-19. NaNose Medical collected samples from 130 patients and sent nanomaterial sensor data to BrainChip’s Research Institute in Perth, Western Australia, which configured and trained its Akida™ neuromorphic processor to interpret the data using AI/ML. The system detected the instances of COVID-19 between a disease group and a healthy control group and Akida learned to recognize patterns of VOC biomarkers associated with an infection within seconds with a high level of accuracy in a minimal time frame. NaNose Medical is currently collecting samples from three primary worldwide locations and will work with BrainChip to evaluate the data.
---
Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath
This article reports on a noninvasive approach in detecting and following-up individuals who are at-risk or have an existing COVID-19 infection, with a potential ability to serve as an epidemic control tool. The proposed method uses a developed breath device composed of a nanomaterial-based hybrid sensor array with multiplexed detection capabilities that can detect disease-specific biomarkers from exhaled breath, thus enabling rapid and accurate diagnosis. An exploratory clinical study with this approach was examined in Wuhan, China, during March 2020. The study cohort included 49 confirmed COVID-19 patients, 58 healthy controls, and 33 non-COVID lung infection controls. When applicable, positive COVID-19 patients were sampled twice: during the active disease and after recovery. Discriminant analysis of the obtained signals from the nanomaterial-based sensors achieved very good test discriminations between the different groups. The training and test set data exhibited respectively 94% and 76% accuracy in differentiating patients from controls as well as 90% and 95% accuracy in differentiating between patients with COVID-19 and patients with other lung infections. While further validation studies are needed, the results may serve as a base for technology that would lead to a reduction in the number of unneeded confirmatory tests and lower the burden on hospitals, while allowing individuals a screening solution that can be performed in PoC facilities. The proposed method can be considered as a platform that could be applied for any other disease infection with proper modifications to the artificial intelligence and would therefore be available to serve as a diagnostic tool in case of a new disease outbreak.
This article is directly referenced in the BRN slide:
Nanose Medical - Nanose -Disease diagnosis - Official Website
Nanose Medical revolutionarily combines the power of nanotechnology with artificial intelligence for rapid and cost-effective disease diagnosis.
nanosemed.com
Nanoscale Sensor Technologies for Disease Detection
Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules
---
WO2021214763A1 - Device and method for rapid detection of viruses - Google Patents
The invention proposes an approach utilizing novel and artificially intelligent hybrid sensor arrays with multiplexed detection capabilities for disease-specific biomarkers from the exhaled breath of a subject. The technology provides a rapid and highly accurate diagnosis in various COVID-19...
patents.google.com
Device and method for rapid detection of viruses
Abstract
The invention proposes an approach utilizing novel and artificially intelligent hybrid sensor arrays with multiplexed detection capabilities for disease-specific biomarkers from the exhaled breath of a subject. The technology provides a rapid and highly accurate diagnosis in various COVID-19 infection and transmission scenarios.
The first dataset was collected with the first-generation device with singe use units that include the sensors of the invention. The dataset included subjects tested with the device at two sites: 35 samples from Northwell NY, and 31 samples from Shamir medical center IL. Each test file consisted of responses from duplicated sensor array, and therefore each test file was split into two sample files, based on the sensor sets. Some of the sensors failed to respond, and therefore datasets that included failed sensors were discarded. The total number of sample files that were analyzed after the error- prone samples were discarded is: Northwell - 35 sample files (representing 24 tested subjects - 17 positives, 7 negatives) and Shamir medical center - 31 sample files (representing 21 tested subjects - 14 positives, 7 negatives). The data was analyzed by Brainchip with a Spiking Neural Network, the adjacent confusion matrix shows the results on the test set. The test set included 31 samples- 21 positives and 10 negatives from 21 tested subjects. Zero out of 21 positive samples were identified correctly which represents 100% sensitivity and 4 out of 10 negative samples were identified correctly which represents 40% specificity. The overall accuracy was 80.65% The second study was performed with the multiuse NaNose sensors installed in Sniffphone device. The dataset included 165 samples taken from 141 subjects tested with Sniffphone device at Zayed Military Hospital - 65 samples from 65 COVID-19 positive subjects and 100 samples from 76 COVID-19 negative subjects (Several negative subjects were sampled two or three times). A Linear discriminative analysis was performed. The adjacent confusion matrix shows the results on the test set that that was completely blind to the training and validation of the model. The test set included 37 samples - 8 positive and 29 negative samples from 27 tested subjects. Seven out of eight positive samples were identified correctly which represents 87.5% sensitivity, and 25 out of the 29 negative samples were identified correctly which represents 86.2% specificity. The overall accuracy was therefore 86.5%.
The same data set was analyzed also by the SNN methodology. To make the SNN most efficient, 34 samples were discarded due to noise or improper vector dimensionality. Thus, the dataset included 131 samples taken from 126 subjects tested with Sniffphone device at Zayed Military Hospital- 62 samples from 62 COVID-19 positive subjects and 69 samples from 64 COVID-19 negative subjects (Several negative subjects were sampled two or three times). The adjacent confusion matrix shows the results on the test set that that was completely blind to the training and validation of the model. The test set included 53 samples - 20 positive and 33 negative samples from 53 tested subjects. Nineteen out of 20 positive samples were identified correctly which represents 95% sensitivity and 29 out of 33 negative samples were identified correctly which represents 87.87 % specificity. The overall accuracy was therefore 90.5%.
---
Israeli company develops 'breathalyzer' COVID-19 test with 98% accuracy
During its preliminary testing, which has still not been completed, the company has seen 98% accuracy in the use of the test, which takes just a few minutes to perform
With the company's "unique algorithm," it claims to be able to have an even higher level of sensitivity and specificity (98%). Such results are higher than existing commercial tests. The algorithm is one which is in standard practice approved both in Israel and around the world. These preliminary results could mean that the test is eligible for FDA approval.
Prince Charles meets with Israeli scientists at Technion University
Charles is honoring Churchill's memory by meeting Professor Haick, one of Israel's leading scientists of the modern age
"SniffPhone has an unparalleled advantage over traditional screening methods: The device is comfortable and painless to use, and provides a simple and cost-effective alternative for medical professionals," Technion University explained in a statement.
Prof. Hossam Haick met with Microsoft founder Bill Gates in South Africa - LNBD
Prof. Hossam Haick met with Microsoft founder Bill Gates in South Africa. Gates, who is working to eradicate infectious diseases in the Third World, wanted to learn about the innovative technology developed by Prof. Haick: an “adhesive bandage” for fast and inexpensive diagnosis of tuberculosis.
PROF. HOSSAM HAICK MET WITH MICROSOFT FOUNDER BILL GATES IN SOUTH AFRICA
---
Previous clinical trials with Nanose:
ClinicalTrials.gov
clinicaltrials.gov
Cancer Diagnoses From Exhaled Breath With Na-nose
ClinicalTrials.gov
clinicaltrials.gov
Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer
ClinicalTrials.gov
clinicaltrials.gov
Diagnosis of Gastric Lesions From Exhaled Breath and Saliva
ClinicalTrials.gov
clinicaltrials.gov
Detection of Placenta Accreta Via Exhaled Women Breath
ClinicalTrials.gov
clinicaltrials.gov
Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples
ClinicalTrials.gov
clinicaltrials.gov
Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples (MS-NANOSE)
ClinicalTrials.gov
clinicaltrials.gov
Application of Nanotechnology and Chemical Sensors for Diagnosis of Decompensated Heart Failure by Respiratory Samples
ClinicalTrials.gov
clinicaltrials.gov
Detection and Identification of Preeclampsia Via Volatile Biomarkers (DIP)
ClinicalTrials.gov
clinicaltrials.gov
Diagnosis of Common Oral Diseases by Signature Volatile Profiles
ClinicalTrials.gov
clinicaltrials.gov
Breath Testing in Early and Late Larynx Cancer
---
News coverage:
| Just breathe: Israeli-made Nano COVID breath test spots every carrier in trial |
Just breathe: Israeli-made Nano COVID breath test spots every carrier in trialTechnion’s Hossam Haick says his breath test eliminates lab processing, and also the need for anyone to touch patients or samples; clinical trial results have been peer-reviewed
www.timesofisrael.com
|
| Prototype ‘breathalyser’ test for Covid-19 shows promise |
Prototype ‘breathalyser’ test for Covid-19 shows promiseIn an ACS Nano paper, a team of researchers have described the development of a prototype device which non-invasively detects Covid-19 in the breath of patients.
|
| Novel COVID-19 Breath Test Detects Disease With 92% Accuracy In Trial |
Novel COVID-19 Breath Test Detects Disease With 92% Accuracy In TrialThe coronavirus breathalyzer was developed by a team led by award-winning scientist Professor Hossam Haick and Dr. Yoav Broza of the Technion.
|
| Toward a coronavirus breathalyzer test |
Toward a coronavirus breathalyzer testResearchers have developed a prototype device that non-invasively detected COVID-19 in the exhaled breath of infected patients.
www.sciencedaily.com
|
| Israel's COVID-19 breathalyzer test prototype promises results in 30 seconds | |
| New prototype device non-invasively detects COVID-19 in exhaled breath of infected patients |
New prototype device non-invasively detects COVID-19 in exhaled breath of infected patientsFew people who have undergone nasopharyngeal swabs for coronavirus testing would describe it as a pleasant experience.
|
| COVID-19 Coronavirus Breathalyzer Test Developed |
COVID-19 Coronavirus Breathalyzer Test DevelopedFew people who have undergone nasopharyngeal swabs for coronavirus testing would describe it as a pleasant experience. The procedure involves sticking a long swab up the nose to collect a sample from the back of the nose and throat, which is then analyzed for SARS-CoV-2 RNA by the reverse-transcript
scitechdaily.com
|
| Novel COVID-19 Breathalyzer Has Potential as Screening Tool |
Novel COVID-19 Breathalyzer Has Potential as Screening Tool – Global Health News Wire
globalhealthnewswire.com
|
| Technion researchers working on emergency projects to fight coronavirus | |
| New breath test sniffs out Covid-19 in 30 seconds |
New breath test sniffs out Covid-19 in 30 seconds - ISRAEL21cBreath test from Technion scientist shows promising early results in sniffing out Covid-19 within 30 seconds.
|
| Prince Charles heralds ‘Israeli geniuses maintaining entire structure of NHS’ |
Prince Charles heralds ‘Israeli geniuses maintaining entire structure of NHS’After a sombre day dominated by remembrance of the Shoah, Charles met innovators, cultural figures and business leaders from across Israeli society
jewishnews.timesofisrael.com
|
| Prince Charles meets with Israeli scientists at Technion University |
---
